Antibodies Market
Market Insights on Antibodies covering sales outlook, demand forecast & up-to-date key trends
Antibodies Market by Disease Indication (Cardiovascular diseases, CNS disorders, Cancer, Autoimmune Disorders), Product Type (Monoclonal antibodies, Polyclonal antibodies, Antibody-drug complexes (ADCs)), End User & Region - Forecast to 2021-2031
Antibodies Market Snapshot
Antibodies Market will grow by 21x in upcoming decade, surpassing US$ 601.614 Billion by the end of 2031, finds Future Market Insights (FMI).
North America is anticipated to dominate the Antibodies Market holding around 45.8% of the overall market share in 2021. The growth can be attributed to rising awareness, increasing government funding to find treatment for chronic ailments and presence of leading market players in U.S. and Canada.
FMI also states that, F. Hoffmann-La Roche Ltd., AbbVie Inc., Johnson & Johnson Services, Inc., Amgen Inc., and Bristol-Myers Squibb Company are leading players operating in the antibodies market. Collectively they will account for 3 out of 4 sales of antibodies across the globe.
Let us know your requirement to get
100% FREE customization
Antibodies Market - Key Points Covered in Study
- Antibodies Market estimates and forecast 2021 – 2031
- Key drivers and restrains impacting Antibodies Market growth
- Segment-wise, Country-wise, and Region-wise Analysis
- Competitive Mapping and Benchmarking
- Brand share and Market Share Analysis
- Key Product Innovations and Regulatory Climate
- COVID-19 Impact On Antibodies Market and How to Navigate
- Recommendation on Key Winning Strategies
Antibodies Market Outlook In Comparison to 2021 – 2031 Forecast
Antibodies are essential for treating medical conditions like autoimmune diseases, cancer, and various type neurological diseases. Certain type of antibodies called immunoglobulin (IG) is used for the prevention of lower respiratory tract infections and diseases caused by vaccinia virus. Rising cases of viral infection will drive the demand for antibodies.
National Stem Cell Foundation (NSCF) has reported that about 4% of global population is affected by some kind of autoimmune diseases. The most common autoimmune diseases are diabetes, multiple sclerosis, Crohn’s disease and rheumatoid arthritis.
Autoimmune diseases also act as a host for multiple chronic ailments. As the prevalence of autoimmune diseases is on the rise, the demand for antibodies is forecast to increase in upcoming years.
In April 2021, Xencor commenced its Phase I clinical trial of its new engineered Interleukin-2 (IL-2) Fc cytokine and XmAb564 antibody therapeutics designed for developing treatment of patients with autoimmune diseases.
The COVID-19 pandemic boosted the demand for antibodies as patients suffering from COVID-19 were highly susceptible to contracting various other ailments and in some cases triggered the autoimmune diseases in the patient.
Zydus Cadila is planning to launch its own antibody cocktail, ZRC-3308, through trials in India. The antibody cocktails are used in COVID-19 patients who are at risk of progressing to severe disease.
Novel biosimilar antibodies manufacturers are slashing their prices to compete with branded antibodies manufacturers especially in European market. With expiration of patents of renowned products, a boost in demand for biosimilar antibodies can be expected in upcoming years.
How do Research and Development Activities Impact Antibodies Sales Outlook?
Surge in research and development activities among pharmaceutical market leaders to develop economical and effective antibodies and biosimilar antibodies are driving the market growth.
In February 2021, Abingdon Health collaborated with Abcam to explore opportunities for their service and portfolio expansion which includes Abcam's reagent portfolio and Abingdon Health’s rapid test contract development and manufacturing services.
In September 2020, Regeneron collaborated with Roche for efficient clinical trials of their monoclonal antibody treatment (REGN-COV2) for COVID-19.
Rising cases of multiple sclerosis and Parkinson’s disease among older population is key factor fueling the demand for antibodies. There is an urgency to develop personalized and cheap medicines, advanced therapeutics, and novel and effective treatments in middle income countries. This is expected to positively influence the sales of antibodies.
In 2021, Berkeley Lights, a digital cell biology company joined hands with Genovac, an antibody discovery company to readily access the right antibodies in the shortest amount of time with the help of modern technology.
Considering this, the rising application of antibodies in chronic diseases treatment will create scope for market expansion in the near future.
Find your sweet spots for generating winning opportunities in this market.
Talk to AnalystHow Is Increasing Production of Bio-similar Antibodies driving Demand?
Biosimilar antibodies are experiencing heavy demand as they are inexpensive in comparison with human monoclonal antibodies and they have very few side effects.
In 2020, Johnson and Johnson reported US$ 3.75 Bn achieved through the sales of Remicade. According to Pfizer, Inflectra, the biosimilar competitor of Remicade generated US$ 659 Mn in 2020.
U.S. Food and Drug Administration (FDA) approved a biosimilar of Remicade called “Avsola” in December 2019, and are now eligible for producing biologics product all over the world.
Increasing demand for biosimilar antibodies in treatment of rheumatoid arthritis along with high patient acceptance rate will boost the market growth.
One of the leaders in prescription medicines, Pfizer received the EU approval for biosimilar antibody therapeutics “Amsparity” for Crohn’s disease, psoriasis, and psoriatic arthritis in February 2020.
Elevated new drug approval rates and products in the clinical trials in pharmaceutical companies will drive the market in upcoming years.
Antibodies Market Country-wise Analysis
Why Is U.S Dominating The Global Antibodies Market?
The U.S. is the leading manufacturer of antibodies owing to modern healthcare infrastructural facilities and presence of leading market players in the country. Increasing purchasing power of consumers along with increasing government funding will drive the market growth.
National Health Accounts by Centers for Medicare & Medicaid Services (CMS) in its report states that healthcare spending in U.S. grew by around 4.6% in 2019. Rising cases of cancer and autoimmune diseases in the country will further increase the demand for antibodies.
National Stem Cell Foundation (NSCF) states that, autoimmune diseases are the third most common reason of chronic ailments in U.S. Increasing cases of diabetes and multiple sclerosis in the country will positively influence the demand for antibodies.
In February 2021, U.S. Food and Drug Administration (FDA) issued the authorization for bamlanivimab and etesevimab monoclonal antibodies administered together for the treatment of mild to moderate COVID-19 in adults and pediatric patients suffering for SARS-CoV-2 and are succeptible to progressing to severe case. This will accelerate the demand for antibodies in the country for years to come.
What Are The Factors Driving Antibodies Demand In Saudi Arabia?
GCC countries led by Saudi Arabia is emphasizing on early diagnosis and screening of cancer to elevate the survival rate and chance of successful treatment. Increasing screening and diagnosis using biosimilar antibodies therapeutics will bode well with market growth in the region.
Around 1291 new cases of childhood cancer were reported in Saudi Arabia in 2020, as per the report from World Health Organization (WHO). Increasing establishment of biotechnology research and development centers to develop cancer monoclonal antibodies will drive the market growth in upcoming years.
Market Players are working towards developing antibodies which are effective in treating COVID-19. Biotech company SaudiVax and U.S. firm Abound Bio jointly announced a licensing agreement for developing COVID-19 treatment.
The companies discovered a human monoclonal antibodies showcasing high potency in neutralizing activity against SARS-CoV-2. This will create growth opportunities in Saudi Arabia.
How Will Antibodies Market Growth Unfold in China?
World Bank evaluated that the healthcare expenditure in China was accounted for 5.35% of its gross domestic product (GDP) in 2018. Rising geriatric population and associated ailments will drive the market growth in upcoming years.
Development and production of antibodies in China is expected to increase significantly owing to increasing government investment towards drugs development coupled with growing awareness about various medical ailments like rheumatoid arthritis, cancer and infections.
Chine developed its first U.S. Food and Drug Administration (FDA) approved antibody in March 2018.The antibody named “Trogarzo” was useful in treating resistant HIV infections. Similarly more than ten other China made biologics are under clinical trials.
The government also started a “Chinese Antibody Society” with the aim to assist in speedy FDA approval as well as ensure effective marketing of China made antibody-based therapeutics.
These initiatives are expected to reflect positively on the China market, presenting conducive environment for the growth of antibodies sales.
What is Influencing Antibodies Market Growth In India?
Indian antibodies market is anticipated to grow at a rapid pace owing to rising cases of cancer and cardiovascular diseases along with development of healthcare system in the country.
As per the data from Global Cancer Observatory, 1.322 million new cancer cases were registered in India in 2020, while 2.72 million people had cancer for 5 years. Surge in cancer patients will drive the demand for monoclonal antibodies for cancer treatment.
Antibodies are finding its use in developing treatment for ongoing COVID-19 pandemic. World Health Organization has reported that around 29.97 million people were infected with COVID-19 in India as of June 2021. These numbers indicate huge potential for monoclonal antibodies market in India.
In 2021, Roche collaborated with Cipla to provide monoclonal antibody drugs called “REGEN-COV2”. REGEN-COV2 is a cocktail of monoclonal antibodies casirivimab and imdevimab and has received strict medical emergency approval.
Rapid technological advancements, increasing government funding to make the treatment affordable, and increasing consumer spending on healthcare will create opportunities for growth in India.
An unified Market Research Subscription Platform, built for today’s disparate research needs.
Antibodies Market Category-wise Insights
Why Are Cancer Antibodies Gaining Popularity?
Rising prevalence of non-Hodgkin lymphoma and other type of cancer has fuelled the demand for cancer antibodies for developing noninvasive and safe treatment options. With focus on cancer research increasing, the antibodies market outlook for the upcoming decade will remain positive.
Which Product Will Register High Demand?
Monoclonal antibodies are predicted to showcase elevated demand throughout the forecast period owing to rising drug approval rates. Besides this, sales in this category will rise in response to the increasing cases of rheumatoid arthritis, psoriasis, and asthma in geriatric population across the globe. The rising demand for effective treatment of aforementioned chronic ailments will remain a chief growth driver in this category.
Who is the Leading End User of Antibodies?
Hospitals are expected to generate highest demand throughout the forecast period. Growing pool of patients and faster accessibility to healthcare will elevate the demand in Hospitals.
Hospitals around the world register a higher footfall of patients as they offer expert care and infrastructure required for administering necessary treatment. Antibodies demand in hospitals multiplied amid COVID-19 outbreak.
Even as governments roll out vaccination drives to contain the pandemic, hospitals will remain dominant end user on account of rising cases of various types of chronic ailments.
Antibodies Market - Competitive Landscape
Future Market Insights (FMI) has found that market players are working towards developing new antibodies to treat cancer and other diseases. They are also researching to create long acting antibody drugs to reduce healthcare cost.
In order to gain a competitive edge in the antibodies market, key players are developing oral and noninvasive treatments using antibodies to treat chronic ailments. Strategic merger and acquisition for portfolio expansion is in the cards as well.
On June 11, 2021, Novartis published its new Phase II data of an investigational oral treatment “iptacopan”, developed for treating paroxysmal nocturnal hemoglobinuria (PNH). The study indicated that, during 12 weeks of iptacopan monotherapy treatment no unexpected safety issues were reported which led to rapid and durable transfusion-free improvement of hemoglobin levels in the majority of patients.
In August 2020, Johnson & Johnson entered into final agreement to acquire Momenta Pharmaceuticals Inc. for around US$ 6.5 Bn. Momenta Pharmaceuticals Inc. is a market leader in developing novel therapies for immune-mediated diseases.
The acquisition will allow the Janssen Pharmaceutical Companies of Johnson & Johnson to expand its product portfolio in immune-mediated diseases while driving growth through expansion into autoantibody-driven disease.
Antibodies Market – Report Scope
|
Attribute |
Details |
|
Forecast Period |
2021 – 2031 |
|
Historical Data Available for |
2016 – 2026 |
|
Market Analysis |
US$ Mn for Value & Units for Volume |
|
Key Countries Covered |
US, Canada, Germany, U.K., France, Italy, Spain, Russia, China, Japan, South Korea, India, Thailand, Malaysia, Indonesia, Australia, New Zealand, GCC Countries, Turkey, Northern Africa, and South Africa |
|
Key Segments Covered |
By Disease Indication, End user, Product Type, Region |
|
Key Companies Profiled |
|
|
Report Coverage |
Market Overview, Market Background, Market Forecast, Segmental Analysis, Regional Profiling and Competition Analysis |
|
Customization & Pricing |
Available upon Request |
Key Segments Covered in Antibodies Market Study
By Disease Indication
- Cardiovascular diseases
- CNS disorders
- Cancer
- Autoimmune Disorders
By Product Type
- Monoclonal antibodies
- Polyclonal antibodies
- Antibody-drug complexes (ADCs)
By End User
- Hospitals
- Long-term Care Facilities
- Research institutes
By Region
- North America
- Latin America
- Western Europe
- Eastern Europe
- Asia Pacific excluding Japan
- Japan
- Middle East and Africa (MEA)
Frequently Asked Questions
Driven by increasing research in monoclonal antibodies in treating autoimmune disease, the antibodies market size is forecast to reach US$ 186.865 Billion in 2021.
Between 2016 and 2020, the antibodies market grew at 9.50% CAGR owing to increasing cases of cancer and diabetes in last 5 years.
The market valuation of antibiotics is forecast to reach US$ 601.607 Billion by the end of 2031.
U.S., Switzerland, and France are leading producers of the antibodies owing to presence of leading market players and dedicated research facilities in these countries.
Demand registered in North America will continue rising, backed by presence of leading market players in the U.S. and Canada, the North America market is predicted to account for 49.2% market share by 2031.
F. Hoffmann-La Roche Ltd., AbbVie Inc., Johnson & Johnson Services Inc., Amgen Inc., and Bristol-Myers Squibb Company are the top five companies operating in the market.
Top five players account for nearly 75% of the antibodies market in 2021.
Antibodies sales will increase at 11.3% CAGR in Europe, backed by rising demand in the U.K., Germany and other countries.
Leading countries driving demand in the antibodies market are U.S., Japan, China, U.K., and Canada.
As of 2021, Japan and China holds around 10.3% and 4.3% share respectively in the global antibodies market.
Table of Content
1. Executive Summary
2. Assumptions and Acronyms
3. Research Methodology
4. Market Overview
4.1. Introduction
4.1.1. Market Definition
4.1.2. Market Taxonomy
4.1.3. Market Product Type Overview
4.1.4. Overview
4.2. Market Dynamics
4.2.1. Drivers
4.2.2. Restraints
4.2.3. Opportunity
4.3. Regulations
5. Global Market Forecast
5.1. Market Value (US$ Mn) Forecast
5.1.1. Y-o-Y Growth Projections
5.1.2. Absolute $ Opportunity
5.2. Market Trends
5.2.1. Market Share, By Region
5.2.2. Market Share, By Product Type
5.2.3. Market Share, By End User
5.2.4. Market Share, By Disease Indication
6. Global Market Analysis, By Product Type
6.1. Introduction
6.1.1. Y-o-Y Growth Comparison, By Product Type
6.1.2. Market Share & Basis Point (BPS) Analysis, By Product Type
6.2. Market Forecast, By Product Type
6.2.1. Monoclonal antibodies
6.2.1.1. Absolute $ Opportunity
6.2.1.2. Market Value (US$ Mn) Forecast
6.2.2. Polyclonal antibodies
6.2.2.1. Absolute $ Opportunity
6.2.2.2. Market Value (US$ Mn) Forecast
6.2.3. Antibody-drug complexes (ADCs)
6.2.3.1. Absolute $ Opportunity
6.2.3.2. Market Value (US$ Mn) Forecast
6.2.4. Market Attractiveness Analysis, By Product Type
6.2.5. Prominent Trends
7. Global Market Analysis, By Disease Indication
7.1. Introduction
7.1.1. Y-o-Y Growth Comparison, By Disease Indication
7.1.2. Market Share & Basis Point (BPS) Analysis, By Disease Indication
7.2. Market Forecast, By Disease Indication
7.2.1. Cardiovascular diseases
7.2.1.1. Absolute $ Opportunity
7.2.1.2. Market Value (US$ Mn) Forecast
7.2.2. CNS disorders
7.2.2.1. Absolute $ Opportunity
7.2.2.2. Market Value (US$ Mn) Forecast
7.2.3. Cancer
7.2.3.1. Absolute $ Opportunity
7.2.3.2. Market Value (US$ Mn) Forecast
7.2.4. Autoimmune Disorders
7.2.4.1. Absolute $ Opportunity
7.2.4.2. Market Value (US$ Mn) Forecast
7.2.5. Market Attractiveness Analysis, By Disease Indication
7.2.6. Prominent Trends
8. Global Market Analysis, By End User
8.1. Introduction
8.1.1. Y-o-Y Growth Comparison, By End User
8.1.2. Market Share & Basis Point (BPS) Analysis, By End User
8.2. Market Forecast, By End User
8.2.1. Hospitals
8.2.1.1. Absolute $ Opportunity
8.2.1.2. Market Value (US$ Mn) Forecast
8.2.2. Long-term Care Facilities
8.2.2.1. Absolute $ Opportunity
8.2.2.2. Market Value (US$ Mn) Forecast
8.2.3. Research institutes
8.2.3.1. Absolute $ Opportunity
8.2.3.2. Market Value (US$ Mn) Forecast
8.2.4. Market Attractiveness Analysis, By End User
8.2.5. Prominent Trends
9. Global Market Analysis, By Region
9.1. Introduction
9.1.1. Y-o-Y Growth Projections, By Region
9.1.2. Market Share & Basis Point (BPS) Analysis, By Region
9.2. Market Forecast, By Region
9.2.1. North America Market Value (US$ Mn) Forecast
9.2.2. Latin America Market Value (US$ Mn) Forecast
9.2.3. Western Europe Market Value (US$ Mn) Forecast
9.2.4. Eastern Europe Market Value (US$ Mn) Forecast
9.2.5. Asia Pacific Excl. Japan Market Value (US$ Mn) Forecast
9.2.6. Japan Market Value (US$ Mn) Forecast
9.2.7. MEA Market Value (US$ Mn) Forecast
9.3. Regional Attractiveness Analysis
10. North America Market Analysis
10.1. Introduction
10.1.1. Y-o-Y Growth Projections, By Country
10.1.2. Market Share & Basis Point (BPS) Analysis, By Country
10.2. Key Regulations
10.3. Key Trends
10.4. North America Market Forecast
10.4.1. Market Value (US$ Mn) Forecast, By Country
10.4.1.1. S. Absolute $ Opportunity
10.4.1.2. Canada Absolute $ Opportunity
10.4.2. Market Value (US$ Mn) Forecast, By Product Type
10.4.2.1. Monoclonal antibodies
10.4.2.2. Polyclonal antibodies
10.4.2.3. Antibody-drug complexes (ADCs)
10.4.3. Market Value (US$ Mn) Forecast, By Disease Indication
10.4.3.1. Cardiovascular diseases
10.4.3.2. CNS disorders
10.4.3.3. Cancer
10.4.3.4. Autoimmune Disorders
10.4.4. Market Value (US$ Mn) Forecast, By End User
10.4.4.1. Hospitals
10.4.4.2. Long-term Care Facilities
10.4.4.3. Research institutes
10.4.5. Market Attractiveness Analysis
10.4.5.1. By Country
10.4.5.2. By Product Type
10.4.5.3. By End User
10.4.5.4. By Disease Indication
10.4.6. Drivers & Restraints: Impact Analysis
11. Latin America Market Analysis
11.1. Introduction
11.1.1. Y-o-Y Growth Projections, By Country
11.1.2. Market Share & Basis Point (BPS) Analysis, By Country
11.2. Key Regulations
11.3. Key Trends
11.4. Latin America Market Forecast
11.4.1. Market Value (US$ Mn) Forecast, By Country
11.4.1.1. Argentina Absolute $ Opportunity
11.4.1.2. Brazil Absolute $ Opportunity
11.4.1.3. Mexico Absolute $ Opportunity
11.4.1.4. Rest of Latin America Absolute $ Opportunity
11.4.2. Market Value (US$ Mn) Forecast, By Product Type
11.4.2.1. Monoclonal antibodies
11.4.2.2. Polyclonal antibodies
11.4.2.3. Antibody-drug complexes (ADCs)
11.4.3. Market Value (US$ Mn) Forecast, By Disease Indication
11.4.3.1. Cardiovascular diseases
11.4.3.2. CNS disorders
11.4.3.3. Cancer
11.4.3.4. Autoimmune Disorders
11.4.4. Market Value (US$ Mn) Forecast, By End User
11.4.4.1. Hospitals
11.4.4.2. Long-term Care Facilities
11.4.4.3. Research institutes
11.4.5. Market Attractiveness Analysis
11.4.5.1. By Country
11.4.5.2. By Product Type
11.4.5.3. By End User
11.4.5.4. By Disease Indication
11.4.6. Drivers & Restraints: Impact Analysis
12. Western Europe Market Analysis
12.1. Introduction
12.1.1. Y-o-Y Growth Projections, By Country
12.1.2. Market Share & Basis Point (BPS) Analysis, By Country
12.2. Key Regulations
12.3. Key Trends
12.4. Western Europe Market Forecast
12.4.1. Market Value (US$ Mn) Forecast, By Country
12.4.1.1. K. Absolute $ Opportunity
12.4.1.2. Germany Absolute $ Opportunity
12.4.1.3. France Absolute $ Opportunity
12.4.1.4. Spain Absolute $ Opportunity
12.4.1.5. Italy Absolute $ Opportunity
12.4.1.6. Nordic Countries Absolute $ Opportunity
12.4.1.7. Rest of Western Europe Absolute $ Opportunity
12.4.2. Market Value (US$ Mn) Forecast, By Product Type
12.4.2.1. Monoclonal antibodies
12.4.2.2. Polyclonal antibodies
12.4.2.3. Antibody-drug complexes (ADCs)
12.4.3. Market Value (US$ Mn) Forecast, By Disease Indication
12.4.3.1. Cardiovascular diseases
12.4.3.2. CNS disorders
12.4.3.3. Cancer
12.4.3.4. Autoimmune Disorders
12.4.4. Market Value (US$ Mn) Forecast, By End User
12.4.4.1. Hospitals
12.4.4.2. Long-term Care Facilities
12.4.4.3. Research institutes
12.4.5. Market Attractiveness Analysis
12.4.5.1. By Country
12.4.5.2. By Product Type
12.4.5.3. By End User
12.4.5.4. By Disease Indication
12.4.6. Drivers & Restraints: Impact Analysis
13. Eastern Europe Market Analysis
13.1. Introduction
13.1.1. Y-o-Y Growth Projections, By Country
13.1.2. Market Share & Basis Point (BPS) Analysis, By Country
13.2. Key Regulations
13.3. Key Trends
13.4. Eastern Europe Market Forecast
13.4.1. Market Value (US$ Mn) Forecast, By Country
13.5. Poland Absolute $ Opportunity
13.6. Russia Absolute $ Opportunity
13.7. Rest of Eastern Europe Absolute $ Opportunity
13.7.1. Market Value (US$ Mn) Forecast, By Product Type
13.7.1.1. Monoclonal antibodies
13.7.1.2. Polyclonal antibodies
13.7.1.3. Antibody-drug complexes (ADCs)
13.7.2. Market Value (US$ Mn) Forecast, By Disease Indication
13.7.2.1. Cardiovascular diseases
13.7.2.2. CNS disorders
13.7.2.3. Cancer
13.7.2.4. Autoimmune Disorders
13.7.3. Market Value (US$ Mn) Forecast, By End User
13.7.3.1. Hospitals
13.7.3.2. Long-term Care Facilities
13.7.3.3. Research institutes
13.7.4. Market Attractiveness Analysis
13.7.4.1. By Country
13.7.4.2. By Product Type
13.7.4.3. By End User
13.7.4.4. By Disease Indication
13.7.5. Drivers & Restraints: Impact Analysis
14. Asia Pacific Excl. Japan Market Analysis
14.1. Introduction
14.1.1. Y-o-Y Growth Projections, By Country
14.1.2. Market Share & Basis Point (BPS) Analysis, By Country
14.2. Key Regulations
14.3. Key Trends
14.4. Asia Pacific Excl. Japan Market Forecast
14.4.1. Market Value (US$ Mn) Forecast, By Country
14.4.1.1. China Absolute $ Opportunity
14.4.1.2. India Absolute $ Opportunity
14.4.1.3. ASEAN Absolute $ Opportunity
14.4.1.4. Australia & New Zealand Absolute $ Opportunity
14.4.1.5. Rest of APEJ Absolute $ Opportunity
14.4.2. Market Value (US$ Mn) Forecast, By Product Type
14.4.2.1. Monoclonal antibodies
14.4.2.2. Polyclonal antibodies
14.4.2.3. Antibody-drug complexes (ADCs)
14.4.3. Market Value (US$ Mn) Forecast, By Disease Indication
14.4.3.1. Cardiovascular diseases
14.4.3.2. CNS disorders
14.4.3.3. Cancer
14.4.3.4. Autoimmune Disorders
14.4.4. Market Value (US$ Mn) Forecast, By End User
14.4.4.1. Hospitals
14.4.4.2. Long-term Care Facilities
14.4.4.3. Research institutes
14.4.5. Market Attractiveness Analysis
14.4.5.1. By Country
14.4.5.2. By Product Type
14.4.5.3. By End User
14.4.5.4. By Disease Indication
14.4.6. Drivers & Restraints: Impact Analysis
15. Japan Market Analysis
15.1. Introduction
15.2. Key Regulations
15.3. Key Trends
15.4. Japan Market Forecast
15.4.1. Market Value (US$ Mn) Forecast, By Product Type
15.4.1.1. Monoclonal antibodies
15.4.1.2. Polyclonal antibodies
15.4.1.3. Antibody-drug complexes (ADCs)
15.4.2. Market Value (US$ Mn) Forecast, By Disease Indication
15.4.2.1. Cardiovascular diseases
15.4.2.2. CNS disorders
15.4.2.3. Cancer
15.4.2.4. Autoimmune Disorders
15.4.3. Market Value (US$ Mn) Forecast, By End User
15.4.3.1. Hospitals
15.4.3.2. Long-term Care Facilities
15.4.3.3. Research institutes
15.4.4. Market Attractiveness Analysis
15.4.4.1. By Product Type
15.4.4.2. By End User
15.4.4.3. By Disease Indication
15.4.5. Drivers & Restraints: Impact Analysis
16. MEA Market Analysis
16.1. Introduction
16.1.1. Y-o-Y Growth Projections, By Country
16.1.2. Market Share & Basis Point (BPS) Analysis, By Country
16.2. Key Regulations
16.3. Key Trends
16.4. MEA Market Forecast
16.4.1. Market Value (US$ Mn) Forecast, By Country
16.4.1.1. GCC Countries Absolute $ Opportunity
16.4.1.2. South Africa Absolute $ Opportunity
16.4.1.3. North Africa Absolute $ Opportunity
16.4.1.4. Rest of MEA Absolute $ Opportunity
16.4.2. Market Value (US$ Mn) Forecast, By Product Type
16.4.2.1. Monoclonal antibodies
16.4.2.2. Polyclonal antibodies
16.4.2.3. Antibody-drug complexes (ADCs)
16.4.3. Market Value (US$ Mn) Forecast, By Disease Indication
16.4.3.1. Cardiovascular diseases
16.4.3.2. CNS disorders
16.4.3.3. Cancer
16.4.3.4. Autoimmune Disorders
16.4.4. Market Value (US$ Mn) Forecast, By End User
16.4.4.1. Hospitals
16.4.4.2. Long-term Care Facilities
16.4.4.3. Research institutes
16.4.5. Market Attractiveness Analysis
16.4.5.1. By Country
16.4.5.2. By Product Type
16.4.5.3. By End User
16.4.5.4. By Disease Indication
16.4.6. Drivers & Restraints: Impact Analysis
17. Competition Landscape
17.1. Company Share Analysis
17.2. Competition Dashboard
17.3. Company Profiles Inclusions
17.3.1. Revenue
17.3.2. Products/Brand Offerings
17.3.3. Key developments
17.3.4. SWOT Analysis
17.4. Company Profiled
17.4.1. Novartis AG
17.4.2. Hoffmann-La Roche Ltd.
17.4.3. Johnson & Johnson Services, Inc.
17.4.4. Takeda Pharmaceutical Company Limited
17.4.5. Amgen Inc.
17.4.6. Biogen Inc.
17.4.7. Bristol-Myers Squibb Company
17.4.8. AbbVie Inc.
17.4.9. Sanofi
17.4.10. Eli Lilly and Co.
Let us know your requirement to get
100% FREE customization
List of Tables
Table 01: Global Market Value (US$ Mn) Analysis and Forecast By Drug Type, 2021 – 2031
Table 02: Global Market Value (US$ Mn) Analysis and Forecast By End User, 2021 – 2031
Table 03: Global Market Value (US$ Mn) Analysis and Forecast By Indication, 2021 – 2031
Table 04: Global Market Value (US$ Mn) Analysis and Forecast By Region, 2021 – 2031
Table 05: North America Market Value (US$ Mn) Forecast By Country, 2021 – 2031
Table 06: North America Market Value (US$ Mn) Analysis and Forecast By Drug Type, 2021 – 2031
Table 07: North America Market Value (US$ Mn) Analysis and Forecast By End User, 2021 – 2031
Table 08: North America Market Value (US$ Mn) Analysis and Forecast By Indication, 2021 – 2031
Table 09: Latin America Market Value (US$ Mn) Forecast By Country, 2021 – 2031
Table 10: Latin America Market Value (US$ Mn) Analysis and Forecast By Drug Type, 2021 – 2031
Table 11: Latin America Market Value (US$ Mn) Analysis and Forecast By End User, 2021 – 2031
Table 12: Latin America Market Value (US$ Mn) Analysis and Forecast By Indication, 2021 – 2031
Table 13: Western Europe Market Value (US$ Bn) Forecast By Country, 2021 – 2031
Table 14: Western Europe Market Value (US$ Mn) Analysis and Forecast By Drug Type, 2021 – 2031
Table 15: Western Europe Market Value (US$ Mn) Analysis and Forecast By End User, 2021 – 2031
Table 16: Western Europe Market Value (US$ Mn) Analysis and Forecast By Indication, 2021 – 2031
Table 17: Eastern Europe Market Value (US$ Mn) Forecast By Country, 2021 – 2031
Table 18: Eastern Europe Market Value (US$ Mn) Analysis and Forecast By Drug Type, 2021 – 2031
Table 19: Eastern Europe Market Value (US$ Mn) Analysis and Forecast By End User, 2021 – 2031
Table 20: Eastern Europe Market Value (US$ Mn) Analysis and Forecast By Indication, 2021 – 2031
Table 21: APEJ Market Value (US$ Mn) Forecast By Country, 2021 – 2031
Table 22: APEJ Market Value (US$ Mn) Analysis and Forecast By End User, 2021 – 2031 APEJ Market BPS Analysis, Market
Table 23: APEJ Market Value (US$ Mn) Analysis and Forecast By Indication, 2021 – 2031
Table 24: Japan Market Value (US$ Mn) Analysis and Forecast By Drug Type, 2021 – 2031
Table 25: Japan Market Value (US$ Mn) Analysis and Forecast By End User, 2021 – 2031
Table 26: Japan Market Value (US$ Mn) Analysis and Forecast By Indication, 2021 – 2031
Table 27: MEA Market Value (US$ Mn) Forecast By Country, 2021 – 2031
Table 28: MEA Market Value (US$ Mn) Analysis and Forecast By Drug Type, 2021 – 2031
Table 29: MEA Market Value (US$ Mn) Analysis and Forecast By End User, 2021 – 2031
Table 30: MEA Market Value (US$ Mn) Analysis and Forecast By Indication, 2021 – 2031
Find your sweet spots for generating winning opportunities in this market.
Talk to AnalystList of Charts
Figure 01: Global Antibody Market Split By Drug Type (2021)
Figure 02: Global Antibody Market Split By Disease Indication (2021)
Figure 03: Global Antibody Market Split By End User (2021)
Figure 04: Global Antibody Market Split By By Region (2021)
Figure 05: Global Market BPS Analysis (%) By Drug Type, 2021 & 2031
Figure 06: Global Market Attractiveness Analysis By Drug Type, 2021 – 2031
Figure 07: Global Market Y-o-Y growth (%) By Drug Type, 2021 – 2031
Figure 08: Global Market Absolute $ Opportunity (US$ Bn) By Monoclonal Segment, 2021 – 2031
Figure 09: Global Market Absolute $ Opportunity (US$ Bn) By Polyclonal Segment, 2021 – 2031
Figure 10: Global Market Absolute $ Opportunity (US$ Bn) By Antibody-drug Complexes (ADC) Drug Type Segment, 2021 – 2031
Figure 11: Global Market BPS Analysis (%) By End User, 2021 & 2031
Figure 12: Global Market Attractiveness Analysis By End User, 2021 – 2031
Figure 13: Global Market Y-o-Y growth (%) By End User, 2021 – 2031
Figure 14: Global Market Absolute $ Opportunity (US$ Bn) By Hospitals Segment, 2021 – 2031
Figure 15: Global Market Absolute $ Opportunity (US$ Bn) By Long-term Care Facilities Segment, 2021 – 2031
Figure 16: Global Market Absolute $ Opportunity (US$ Bn) By Research Institutes Drug Type Segment, 2021 – 2031
Figure 17: Global Market BPS Analysis (%) By Indication, 2021 & 2031
Figure 18: Global Market Attractiveness Analysis By Indication, 2021 – 2031
Figure 19: Global Market Y-o-Y growth (%) By Indication, 2021 – 2031
Figure 20: Global Market Absolute $ Opportunity (US$ Bn) By CNS Disorders Segment, 2021 – 2031
Figure 21: Global Market Absolute $ Opportunity (US$ Bn) By Cardiovascular Diseases Segment, 2021 – 2031
Figure 22: Global Market Absolute $ Opportunity (US$ Mn) By Cancer Segment, 2021 – 2031
Figure 23: Global Market Absolute $ Opportunity (US$ Bn) By Autoimmune Disorders Segment, 2021 – 2031
Figure 24: Global Market BPS Analysis (%) By Region, 2021 & 2031
Figure 25: Global Market Attractiveness Analysis By Region, 2021 – 2031
Figure 26: Global Market Y-o-Y growth (%) By Region, 2021 – 2031
Figure 27: North America Market Absolute $ Opportunity (US$ Bn), 2021 – 2031
Figure 28: Latin America Market Absolute $ Opportunity (US$ Bn), 2021 – 2031
Figure 29: Global Market BPS Analysis (%) By Drug Type, 2021 & 2031
Figure 30: Global Market Attractiveness Analysis By Drug Type, 2021 – 2031
Figure 31: Global Market Y-o-Y growth (%) By Drug Type, 2021 – 2031
Figure 32: Global Market Absolute $ Opportunity (US$ Bn) By Monoclonal Segment, 2021 – 2031
Figure 33: Global Market Absolute $ Opportunity (US$ Bn) By Polyclonal Segment, 2021 – 2031
Figure 34: Global Market Absolute $ Opportunity (US$ Bn) By Antibody-drug Complexes (ADC) Drug Type Segment, 2021 – 2031
Figure 35: Global Market BPS Analysis (%) By End User, 2021 & 2031
Figure 36: Global Market Attractiveness Analysis By End User, 2021 – 2031
Figure 37: Global Market Y-o-Y growth (%) By End User, 2021 – 2031
Figure 38: Global Market Absolute $ Opportunity (US$ Bn) By Hospitals Segment, 2021 – 2031
Figure 39: Global Market Absolute $ Opportunity (US$ Bn) By Long-term Care Facilities Segment, 2021 – 2031
Figure 40: Global Market Absolute $ Opportunity (US$ Bn) By Research Institutes Drug Type Segment, 2021 – 2031
Figure 41: Global Market BPS Analysis (%) By Indication, 2021 & 2031
Figure 42: Global Market Attractiveness Analysis By Indication, 2021 – 2031
Figure 43: Global Market Y-o-Y growth (%) By Indication, 2021 – 2031
Figure 44: Global Market Absolute $ Opportunity (US$ Bn) By CNS Disorders Segment, 2021 – 2031
Figure 45: Global Market Absolute $ Opportunity (US$ Bn) By Cardiovascular Diseases Segment, 2021 – 2031
Figure 46: Global Market Absolute $ Opportunity (US$ Mn) By Cancer Segment, 2021 – 2031
Figure 47: Global Market Absolute $ Opportunity (US$ Bn) By Autoimmune Disorders Segment, 2021 – 2031
Figure 48: Global Market BPS Analysis (%) By Region, 2021 & 2031
Figure 49: Global Market Attractiveness Analysis By Region, 2021 – 2031
Figure 50: Global Market Y-o-Y growth (%) By Region, 2021 – 2031
Figure 51: North America Market Absolute $ Opportunity (US$ Bn), 2021 – 2031
Figure 52: Latin America Market Absolute $ Opportunity (US$ Bn), 2021 – 2031
Figure 53: Western Europe Market Absolute $ Opportunity (US$ Bn), 2021 – 2031
Figure 54: Eastern Europe Market Absolute $ Opportunity (US$ Bn), 2021 – 2031
Figure 55: APEJ Market Absolute $ Opportunity (US$ Bn), 2021 – 2031
Figure 56: Japan Market Absolute $ Opportunity (US$ Bn), 2021 – 2031
Figure 57: MEA Market Absolute $ Opportunity (US$ Bn), 2021 – 2031
Figure 58: North America Market BPS Analysis (%) By Country, 2021 & 2031
Figure 59: North America Market Attractiveness Analysis By Country, 2021 – 2031
Figure 60: North America Market Y-o-Y growth (%) By Country, 2021 – 2031
Figure 61: North America Market BPS Analysis (%) By Drug Type, 2021 & 2031
Figure 62: North America Market Attractiveness Analysis By Drug Type, 2021 – 2031
Figure 63: North America Market Y-o-Y growth (%) By Drug Type, 2021 – 2031
Figure 64: North America Market BPS Analysis (%) By End User, 2021 & 2031
Figure 65: North America Market Attractiveness Analysis By End User, 2021 – 2031
Figure 66: North America Market Y-o-Y growth (%) By End User, 2021 – 2031
Figure 67: North America Market BPS Analysis (%) By Indication, 2021 & 2031
Figure 68: North America Market Attractiveness Analysis By Indication, 2021 – 2031
Figure 69: North America Market Y-o-Y growth (%) By Indication, 2021 – 2031
Figure 70: Latin America Market BPS Analysis (%) By Country, 2021 & 2031
Figure 71: Latin America Market Attractiveness Analysis By Country, 2021 – 2031
Figure 72: Latin America Market Y-o-Y growth (%) By Country, 2021 – 2031
Figure 73: Latin America Market BPS Analysis (%) By Drug Type, 2021 & 2031
Figure 74: Latin America Market Attractiveness Analysis By Drug Type, 2021 – 2031
Figure 75: Latin America Market Y-o-Y growth (%) By Drug Type, 2021 – 2031
Figure 76: Latin America Market BPS Analysis (%) By End User, 2021 & 2031
Figure 77: Latin America Market Attractiveness Analysis By End User, 2021 – 2031
Figure 78: Latin America Market Y-o-Y growth (%) By End User, 2021 – 2031
Figure 79: Latin America Market BPS Analysis (%) By Indication, 2021 & 2031
Figure 80: Latin America Market Attractiveness Analysis By Indication, 2021 – 2031
Figure 81: Latin America Market Y-o-Y growth (%) By Indication, 2021 – 2031
Figure 82: Western Europe Market BPS Analysis (%) By Country, 2021 & 2031
Figure 83: Western Europe Market Attractiveness Analysis By Country, 2021 – 2031
Figure 84: Western Europe Market Y-o-Y growth (%) By Country, 2021 – 2031
Figure 85: Western Europe Market BPS Analysis (%) By Drug Type, 2021 & 2031
Figure 86: Western Europe Market Attractiveness Analysis By Drug Type, 2021 – 2031
Figure 87: Western Europe Market Y-o-Y growth (%) By Drug Type, 2021 – 2031
Figure 88: Western Europe Market BPS Analysis (%) By End User, 2021 & 2031
Figure 89: Western Europe Market Attractiveness Analysis By End User, 2021 – 2031
Figure 90: Western Europe Market Y-o-Y growth (%) By End User, 2021 – 2031
Figure 91: Western Europe Market BPS Analysis (%) By Indication, 2021 & 2031
Figure 92: Western Europe Market Attractiveness Analysis By Indication, 2021 – 2031
Figure 93: Western Europe Market Y-o-Y growth (%) By Indication, 2021 – 2031
Figure 94: Eastern Europe Market BPS Analysis (%) By Country, 2021 & 2031
Figure 95: Eastern Europe Market Attractiveness Analysis By Country, 2021 – 2031
Figure 96: Eastern Europe Market Y-o-Y growth (%) By Country, 2021 – 2031
Figure 97: Eastern Europe Market BPS Analysis (%) By Drug Type, 2021 & 2031
Figure 98: Eastern Europe Market Attractiveness Analysis By Drug Type, 2021 – 2031
Figure 99: Eastern Europe Market Y-o-Y growth (%) By Drug Type, 2021 – 2031
Figure 100: Eastern Europe Market BPS Analysis (%) By End User, 2021 & 2031
Figure 101: Eastern Europe Market Attractiveness Analysis By End User, 2021 – 2031
Figure 102: Eastern Europe Market Y-o-Y growth (%) By End User, 2021 – 2031
Figure 103: Eastern Europe Market BPS Analysis (%) By Indication, 2021 & 2031
Figure 104: Eastern Europe Market Attractiveness Analysis By Indication, 2021 – 2031
Figure 105: Eastern Europe Market Y-o-Y growth (%) By Indication, 2021 – 2031
Figure 106: APEJ Market BPS Analysis (%) By Country, 2021 & 2031
Figure 107: APEJ Market Attractiveness Analysis By Country, 2021 – 2031
Figure 108: APEJ Market Y-o-Y growth (%) By Country, 2021 – 2031
Figure 109: APEJ Market BPS Analysis (%) By End User, 2021 & 2031
Figure 110: APEJ Market Attractiveness Analysis By End User, 2021 – 2031
Figure 111: APEJ Market Y-o-Y growth (%) By End User, 2021 – 2031
Figure 112: APEJ Market BPS Analysis (%) By Indication, 2021 & 2031
Figure 113: APEJ Market Attractiveness Analysis By Indication, 2021 – 2031
Figure 114: APEJ Market Y-o-Y growth (%) By Indication, 2021 – 2031
Figure 115: Japan Market BPS Analysis (%) By Drug Type, 2021 & 2031
Figure 116: Japan Market Attractiveness Analysis By Drug Type, 2021 – 2031
Figure 117Japan Market Y-o-Y growth (%) By Drug Type, 2021 – 2031
Figure 118: Japan Market BPS Analysis (%) By End User, 2021 & 2031
Figure 119: Japan Market Attractiveness Analysis By End User, 2021 – 2031
Figure 120: Japan Market Y-o-Y growth (%) By End User, 2021 – 2031
Figure 121: Japan Market BPS Analysis (%) By Indication, 2021 & 2031
Figure 122: Japan Market Attractiveness Analysis By Indication, 2021 – 2031
Figure 123: Japan Market Y-o-Y growth (%) By Indication, 2021 – 2031
Figure 124: MEA Market BPS Analysis (%) By Country, 2021 & 2031
Figure 125: MEA Market Attractiveness Analysis By Country, 2021 – 2031
Figure 126: MEA Market Y-o-Y growth (%) By Country, 2021 – 2031
Figure 127: MEA Market BPS Analysis (%) By Drug Type, 2021 & 2031
Figure 128: MEA Market Attractiveness Analysis By Drug Type, 2021 – 2031
Figure 129: MEA Market Y-o-Y growth (%) By Drug Type, 2021 – 2031
Figure 130: MEA Market BPS Analysis (%) By End User, 2021 & 2031
Figure 131: MEA Market Attractiveness Analysis By End User, 2021 – 2031
Figure 132: MEA Market Y-o-Y growth (%) By End User, 2021 – 2031
Figure 133: MEA Market BPS Analysis (%) By Indication, 2021 & 2031
Figure 134: MEA Market Attractiveness Analysis By Indication, 2021 – 2031
Figure 135: MEA Market Y-o-Y growth (%) By Indication, 2021 – 2031
Need specific information?
Request CustomizationExplore Healthcare Insights
View Reports
